BCR and chronic myelogenous leukemia, BCR-ABL1 positive: In HFpEF patients of a large longitudinal cohort, the mean plasma CML concentration was 2.05 μM in the survivors and 2.42 μM in the non-survivors of the study, and higher plasma CML concentration was significantly and independently associated with higher risk for mortality (Willemsen et al. 2012).